Voxelotor — Discount Pricing
Voxelotor is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Voxelotor Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $68.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Voxelotor
Voxelotor is a prescription medication. Ask your doctor if Voxelotor is right for you.
How to Check Voxelotor Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Voxelotor at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
What Voxelotor is approved for (FDA label)
OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: December 26, 2023.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Voxelotor (FDA label)
Tablets: 300 mg light purple to purple, oval shaped, biconvex, debossed with "G 300" on one side. Tablets: 500 mg light yellow to yellow, oval shaped, biconvex, debossed with "GBT 500" on one side. Tablets for oral suspension: 300 mg light yellow to yellow, round shaped, debossed with "300 D" on one side. • Tablets: 300 mg and 500 mg ( 3 ) • Tablets for oral suspension: 300 mg ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 3c557fac-29ec-483f-b691-8a935d4decc3. SPL document ID: e27a3e07-438e-49d3-aae3-095e9379c7b4. Label effective date: December 26, 2023. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Voxelotor (FDA label)
The following clinically significant adverse reaction is discussed in other sections of the labeling: • Hypersensitivity Reactions [see Contraindications (4) and Warnings and Precautions (5.1) ]. Most common adverse reactions (incidence ≥10% with a difference of >3% compared to placebo) are headache, diarrhea, abdominal pain, nausea, rash, and pyrexia. ( 6.1 ) Most common adverse reactions (incidence >10%) reported in pediatric patients 4 to <12 years are pyrexia, vomiting, rash, abdominal pain, diarrhea, and headache. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Source: FDA prescribing information (DailyMed). Set ID: 3c557fac-29ec-483f-b691-8a935d4decc3. SPL document ID: e27a3e07-438e-49d3-aae3-095e9379c7b4. Label effective date: December 26, 2023. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Voxelotor (FDA label)
OXBRYTA is contraindicated in patients with a history of serious drug hypersensitivity reaction to voxelotor or excipients. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. Prior drug hypersensitivity to voxelotor or excipients. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 3c557fac-29ec-483f-b691-8a935d4decc3. SPL document ID: e27a3e07-438e-49d3-aae3-095e9379c7b4. Label effective date: December 26, 2023. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Voxelotor (FDA label)
• Hypersensitivity Reactions: Observe for signs and symptoms and manage promptly. ( 5.1 ) • Laboratory Test Interference: Perform quantification of hemoglobin species when patient is not receiving OXBRYTA. ( 5.2 ) 5.1 Hypersensitivity Reactions Serious hypersensitivity reactions after administration of OXBRYTA have occurred in <1% of patients treated. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia [see Adverse Reactions (6.1) ] . Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in postmarketing experience with OXBRYTA [see Adverse Reactions (6.2) ] . Patients who develop a combination of skin rash, fever, peripheral eosinophilia, and internal systemic organ involvement (e.g., hepatic, renal, pulmonary) while receiving OXBRYTA should undergo medical evaluation. Advise patients of the signs and symptoms of severe hypersensitivity reactions, including DRESS. If hypersensitivity reactions occur, discontinue OXBRYTA and administer appropriate medical therapy.
Source: FDA prescribing information (DailyMed). Set ID: 3c557fac-29ec-483f-b691-8a935d4decc3. SPL document ID: e27a3e07-438e-49d3-aae3-095e9379c7b4. Label effective date: December 26, 2023. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Voxelotor (FDA label)
• Sensitive CYP3A4 Substrates: Avoid coadministration of sensitive CYP3A4 substrates with a narrow therapeutic index. ( 7.2 ) • Strong or moderate CYP3A4 Inducers: Avoid coadministration with strong or moderate CYP3A4 inducers. If unavoidable, increase the dose of OXBRYTA. ( 2.5 , 2.6 , 7.1 ) 7.1 Effect of Other Drugs on Voxelotor Strong or Moderate CYP3A4 Inducers Coadministration of strong or moderate CYP3A4 inducers may decrease voxelotor plasma and whole blood concentrations and may lead to reduced efficacy. Avoid coadministration of OXBRYTA with strong or moderate CYP3A4 inducers.
Source: FDA prescribing information (DailyMed). Set ID: 3c557fac-29ec-483f-b691-8a935d4decc3. SPL document ID: e27a3e07-438e-49d3-aae3-095e9379c7b4. Label effective date: December 26, 2023. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.